Table 4.
Treatment | HS | 15dAH | MS |
---|---|---|---|
GABA0 | |||
YX | |||
ZN | 107.71 | 86.64 | 113.94 |
LN | 128.58 | 94.32 | 91.73 |
MN | 107.98 | 94.29 | 84.59 |
HN | 119.58 | 91.01 | 116.99 |
YG | |||
ZN | 23.34 | 11.17 | 7.21 |
LN | 30.99 | 21.23 | 7.26 |
MN | 32.81 | 27.22 | 7.22 |
HN | 43.60 | 19.38 | 9.19 |
BS | |||
ZN | 112.70 | 94.30 | 88.34 |
LN | 118.78 | 116.35 | 106.45 |
MN | 110.16 | 129.76 | 79.58 |
HN | 110.25 | 101.03 | 107.46 |
Mean | 87.21 | 73.89 | 68.33 |
GABA250 | |||
YX | |||
ZN | 126.06 | 86.50 | 93.09 |
LN | 107.54 | 81.45 | 95.78 |
MN | 135.41 | 84.23 | 85.73 |
HN | 120.22 | 101.48 | 92.92 |
YG | |||
ZN | 23.20 | 23.28 | 11.37 |
LN | 25.42 | 13.32 | 11.13 |
MN | 26.92 | 23.46 | 7.13 |
HN | 37.92 | 15.46 | 9.11 |
BS | |||
ZN | 111.75 | 123.46 | 136.96 |
LN | 111.03 | 106.26 | 113.61 |
MN | 109.41 | 118.07 | 106.13 |
HN | 99.29 | 110.26 | 80.84 |
Mean | 86.18 | 73.93 | 70.32 |
Analysis of variance | |||
T | 0.22ns | 0.91ns | 0.18ns |
V | 745.94** | 127.65** | 274.74** |
T × V | 2.87ns | 0.15ns | 2.15ns |
N | 0.27ns | 0.87ns | 2.23ns |
T × N | 0.92ns | 3.45* | 2.92* |
V × N | 1.61ns | 0.50ns | 1.18ns |
T × V × N | 0.86ns | 1.50ns | 2.19ns |
Means with different lowercase letter(s) differ statistically at p < .05.
Abbreviations: BS, Basmati‐385; d AH: days after heading; HS, heading stage; MS: maturity stage; YG: Yugengyou14, YX, Yuxiangyouzhan,
Significant at p < .05;
Significant at p < .01; ns: non‐significant.